NAD+ Without Prescription

NAD+ without prescription describes at least three transactions that behave nothing like each other: a research-use sale that never involves a prescriber, a compounded preparation dispensed on a script, and a clinic infusion administered under someone else's clinical judgement.

Sorting them matters, because the regulatory position that applies to one does not carry across to the others, and because the most-repeated claim about NAD+'s status is wrong in a way you can check in about two minutes. This is research material sold for laboratory use, not for human consumption.

NAD+ is nicotinamide adenine dinucleotide, a coenzyme that every cell already makes and spends. It is not a peptide, which matters here only because its regulatory history is genuinely different from the peptides sold beside it.

Three transactions get called NAD+ without prescription

Only the first row is genuinely prescription-free, and it is prescription-free for an unglamorous reason: there is no approved NAD+ injectable product in the United States, so on that route there is nothing for anyone to prescribe. The absence of a prescription step is not permission. It is the shape of a market where no approved product exists.

Where NAD actually sits on FDA's 503A lists

This is the part competing pages get wrong, so here it is against the document.

FDA maintains category lists of bulk drug substances nominated for use in compounding under section 503A. The current version was updated on 14 May 2026, and it contains three entries relevant to anyone reading about NAD+.

There is no NAD entry in Category 2. If you have read that NAD+ is Category 2, or that it is banned from compounding, the source did not open the list. Category 2 is the category for substances where FDA has identified significant safety risks, and in the 14 May 2026 lists it holds six substances: cesium chloride, domperidone, germanium sesquioxide, ibutamoren mesylate, kisspeptin-10, and quinacrine hydrochloride for intrauterine administration. NAD is not among them.

What Category 1 means, in FDA's words

The temptation is to read Category 1 as a green light. It is not, and FDA's own description is precise enough to quote rather than paraphrase.

On its bulk drug substances page, with content current as of 14 May 2026, the agency defines Category 1 as substances that "may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list". Then the operative sentence: "FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met."

Three things follow from that, and all three are worth stating plainly.

It is a non-enforcement position, not an approval. FDA is saying what it does not intend to do, which is a different kind of statement from finding a substance safe and effective. The agency issued the interim policy explicitly to avoid unnecessary disruption to patient treatment while it evaluates the nominated substances.

It addresses compounders, not consumers. The sentence is about action against a compounder. It says nothing about individuals buying research material, and citing it as personal cover is citing the wrong party's position.

And it is conditional and unfinished. The category is titled Bulk Drug Substances Under Evaluation, and the protection applies only where the conditions in the guidance are met.

Under review means the list moves

The word provisional does real work here, and the same document proves it.

The 14 May 2026 lists record GHK-Cu being removed from Category 1 on 22 April 2026 because its nominations were withdrawn, then a nominator clarifying on 5 May 2026 that it had intended to withdraw only the injectable route, then the non-injectable entry being added back, with FDA stating it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027. Three changes to one entry in a matter of weeks.

Nothing in that sequence involves NAD. It is included because it demonstrates what kind of document this is: a working list that changes, not a settled register. A page describing NAD's status as though it were permanent is describing a snapshot and calling it a rule.

The Beta-NAD trap

Read the full entry name. The list contains an item beginning Beta-Nicotinamide Adenine Dinucleotide, and it is in Category 3, the category for substances nominated without adequate support, not Category 1.

It reads like the same substance under a longer name and it sits in a different place. Anyone skimming for "nicotinamide adenine dinucleotide" and reading whichever category appears next to the first match can leave with a confident and incorrect answer in either direction. This is the single most likely source of the Category confusion circulating on this topic, and it costs nothing to avoid: match the whole string, not the first three words.

Is NAD+ legal to buy

The narrow answer is that research suppliers sell it without a prescription, and that this is a statement about the sale rather than about use.

What the checkout is agreeing to is a purchase of material for laboratory research, not for human consumption. Human use is outside what the seller offers, outside what any regulator has evaluated for that product, and outside anything this page endorses. There is no FDA-approved NAD+ injectable to compare it against, which is precisely why the research-use category is where these transactions happen at all.

Two adjacent questions get folded into this one and should not be. NMN and NR are NAD+ precursors, different substances with their own separate regulatory history, and they are widely sold as supplements. We are not stating their status here because we have not verified it, and a supplement capsule is not the same purchase as a gram of injectable-grade powder in any case. Separately, importation is its own question: FDA's guidance states that in most circumstances it is illegal for individuals to import drugs into the US for personal use, which is why a domestic order and an overseas one are not the same transaction dressed differently.

The check that outranks all of the paperwork

Having read this far, it is worth saying which document matters most, and it is not any of the ones above.

In a notice with content current as of 30 October 2024, FDA said it was aware of compounders using food-grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products. Food-grade ingredients, it said, "are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins". It reported adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, consistent with excessive endotoxin levels.

Nobody in that notice was harmed by a category listing. They were harmed by what was in the container. Whatever route you are considering, the question that actually protects you is whether the material is pharmaceutical grade rather than food grade, and whether the batch certificate reports an endotoxin result, the bacterial endotoxins or LAL line, rather than identity and purity alone. Ask a clinic which pharmacy or outsourcing facility supplies its preparation and whether that supplier tests for endotoxins. Ask a vendor for the certificate matching the batch number on the vial. The regulatory position is context. The certificate is the answer.

Common questions

Keep exploring

The format guide covers the difference between a clinic bag, a compounded vial and a sealed gram of powder. The domestic supply page handles importation and the return path, and the retatrutide equivalent shows how differently this question resolves for a research peptide.